Phase 2 N=68 Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Primary: Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses — 7 Participants
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 2 N=17 Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Oral Cavity SCC
Primary: Objective Response Rate Using Pathological Response — 4 Participants
Phase 2 N=60 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Squamous Cell Carcinoma of Oropharynx
Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants
Phase 2 N=20 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Neoplasms, Oral · Mouth Neoplasms
Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Early Phase 1 N=16 Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Oral Squamous Cell Carcinoma
Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response — 9; 6 Participants
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 3 N=303 Erlotinib Prevention of Oral Cancer (EPOC)
Oral Cancer
Primary: Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group. — 55; 18 Participants
Phase 2 N=40 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Carcinoma, Squamous Cell of Head and Neck · Oropharynx Squamous Cell Carcinoma
Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Early Phase 1 N=18 Using MASL to Combat Oral Cancer
Squamous Cell Carcinoma of Head and Neck
Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05
Phase 2 N=30 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.
Oral Cancer
Primary: Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) — 22 Participants
Phase 2 N=21 Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
Mouth Neoplasms
Primary: Change in IL-2 Levels — 1.8; 4.0; 7.9; 2.1 pg/100 gm protein — p=<0.05
Phase 2 N=105 IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Squamous Cell Carcinoma of the Oral Cavity
Primary: Event-free Survival (EFS)- Number of Participants With an Event — 31; 15 Participants
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
N/A N=93 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
Phase 2 N=40 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Response Rate — 37 Participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 1 N=17 Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
Squamous Cell Carcinoma of the Head and Neck
Primary: Maximum Tolerated Dose (MTD) of Olaparib — 50 mg twice daily
Phase 2 N=33 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Leukoplakia, Oral
Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants
Phase 2 N=112 Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 16.2; 14.6; 18.9; 10.0 % of participants
Phase 2 N=28 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
Phase 2 N=52 Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
Head and Neck Cancer
Primary: Major Pathologic Response (MPR) Rate (Primary (Overall) Analysis) — 7; 10 participants
Phase 2 N=41 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Squamous Cell Carcinoma of Mouth · Intraepithelial Neoplasia
Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048